- A growing cohort of US biotech companies is adopting extreme secrecy practices to prevent Chinese pharmaceutical firms from reverse-engineering their drug candidates: Breakthru Medicine, whose team has shepherded 13 drugs through FDA approval, is refusing VC pitches, skipping academic conferences, and accepting money only from a handful of trusted high-net-worth individuals and universities — CEO Steve Potts says if word gets out about what the company is working on, a Chinese firm could beat them to market.
- The fear is grounded in documented precedent: China’s pharmaceutical industry has developed an exceptionally efficient pipeline for identifying promising drug targets from Western research, synthesizing analogues, navigating China’s regulatory process, and reaching market — sometimes before the original Western developer — a capability that turns the traditional biotech business model (publish, raise, develop) into a competitive liability when the target market includes China.
- The secrecy strategy represents a fundamental tension with how biotech innovation has historically worked: academic publication, conference presentation, and VC roadshows are the primary mechanisms by which early-stage biotech raises capital, recruits talent, and establishes scientific credibility — companies that go dark sacrifice these advantages in exchange for competitive protection, a tradeoff that forces them toward alternative funding structures like family offices, university endowments, and strategic corporate partners.
- The trend reflects the broader decoupling of US-China scientific and commercial relationships: what began as export controls on semiconductors and AI chips has spread to pharmaceutical IP, with US companies increasingly treating their drug pipelines as national security-adjacent assets requiring operational security practices more common in defense contracting than in academic medicine.
What Happened?
The Wall Street Journal profiled Breakthru Medicine and a broader pattern of US biotech companies adopting unusual secrecy practices to protect their drug pipelines from Chinese pharmaceutical competitors. Breakthru CEO Steve Potts — whose team has a track record of 13 FDA-approved drugs — has declined to pitch venture capital firms, present at academic conferences, or publicize what the company is working on, fearing that disclosure would allow a Chinese competitor to reach market first. The company takes money only from a small group of trusted individuals and universities.
Why It Matters?
Biotech has historically been one of the most open scientific industries, built on a model of publication, peer review, and collaborative funding that depends on transparency. The secrecy turn threatens to fragment this ecosystem: if the most promising early-stage companies stop publishing and presenting, the scientific community loses the feedback loop that improves drug development broadly. At the same time, the underlying competitive threat is real — Chinese pharmaceutical firms have demonstrated the ability to move from published research to clinical trials to regulatory approval faster than most Western developers, particularly for oncology and metabolic disease targets where the basic science is well-established. The policy question is whether IP protection, trade enforcement, or regulatory barriers are a more sustainable solution than industry-wide secrecy.
What’s Next?
The biotech secrecy trend is likely to accelerate as more companies have bad experiences with IP leakage and as US-China tensions remain elevated. Watch for whether major academic medical centers — which have historically been the main source of early-stage drug discoveries and which depend on publication for faculty promotion and grant funding — start developing two-track research programs: publishable basic science and proprietary translational work. The FDA and NIH will also face pressure to develop guidance on how publicly funded research can be protected from competitive exploitation without undermining the open science principles that justify public research investment.
Source: The Wall Street Journal
